Alectinib - Usual
Preclinical
Alectinib - Usual is one of 2 therapeutic programs targeting ALK-positive Non-small Cell Lung Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in ALK-Positive Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Alecensa
RochePreclinical
Alectinib - Usual
HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ALK-positive Non-small Cell Lung Cancer1 trial
Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.
Active, not recruiting·HHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·Preclinical·NCT05987956·600 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Alectinib - Usual. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]